{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"45.2","upperLimit":"68.4","value":"57.8"},{"groupId":"OG001","lowerLimit":"56.3","upperLimit":"74.3","value":"66.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"160"}],"units":"Participants"}],"description":"OS was defined as time from randomization to death from any cause. Patient alive were censored at date of known alive. The 3-year OS rate was estimated using Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive cisplatin IV or carboplatin IV on day 1. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.\n\nCarboplatin: Given IV\n\nCisplatin: Given IV","id":"OG000","title":"Arm B (Cisplatin or Carboplatin) (Enrolled While Arm C Was Open)"},{"description":"Patients receive capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.\n\nCapecitabine: Given PO","id":"OG001","title":"Arm C (Capecitabine) (Open to Accrual 6/22/2016)"}],"paramType":"NUMBER","populationDescription":"The primary analysis population was all basal-subtype TNBC patients who were concurrently randomized to arms B and C after 6/22/2016 (intent-to-treat population).","reportingStatus":"POSTED","timeFrame":"Assessed every 3 months within 2 years from randomization, every 6 months if 2-3 years","title":"3-year Overall Survival (OS) Rate in Basal-Subtype Patients","type":"SECONDARY","unitOfMeasure":"percentage of participants"}